Multiple sclerosis (MS) is a debilitating neurological disorder caused by malfunctioning immune responses that target the ...

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

Immunotherapy has been one of the most transformative treatments for cancer patients in recent decades, shifting the emphasis ...

Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...

Scientists at Cincinnati Children's have identified how certain immune cells are molecularly programmed to respond faster ...

Scientists have developed a method to reprogram cancer-fighting immune cells directly inside the body, potentially ...

Data are beginning to provide a clearer picture of chimeric antigen receptor T-cell therapy’s benefits and risks in lupus, ...

In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...

Researchers in upstate New York are hopeful the work they’re doing may soon lead to new therapies for more cancer ...

Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...